Quantum drug‑simulation push

Quantum computers are machines built to model the behavior of atoms and electrons directly, the way a flight simulator models turbulence. IonQ is trying to turn that idea into a drug-development business by pairing its hardware with pharmaceutical partners and European research hubs. (ionq.com) IonQ said on June 9, 2025 that it worked with AstraZeneca, Amazon Web Services, and NVIDIA on a quantum-accelerated chemistry workflow for pharmaceutical research. The company said the system cut end-to-end time to solution by more than 20 times versus previous implementations and reduced expected runtime from months to days for a modeled reaction step. (investors.ionq.com) That test focused on a Suzuki-Miyaura reaction, a chemical method used to make small-molecule drugs. AstraZeneca said the work targeted activation barriers for catalyzed reactions tied to route optimization in drug development. (investors.ionq.com) Before that result, IonQ had already moved into AstraZeneca’s BioVentureHub in Gothenburg, Sweden. AstraZeneca BioVentureHub announced on November 25, 2024 that IonQ was establishing a Quantum Computational Chemistry Centre of Excellence there, with an initial focus on chemistry and pharmaceutical development. (azbioventurehub.com) IonQ also built out a European base with QuantumBasel in Switzerland. On December 5, 2024, IonQ said it had put its Forte Enterprise system online at uptownBasel, calling it its first European Innovation Center and the first commercial quantum system in Switzerland. (ionq.com) The company’s pitch is not that quantum computers replace conventional supercomputers. IonQ, Amazon Web Services, and NVIDIA described the June 2025 project as a hybrid setup, with classical computing handling part of the workload and the quantum processor tackling the hardest chemistry calculations. (investors.ionq.com) IonQ spent much of 2025 buying pieces it says will make that system more useful at scale. It completed its acquisition of Qubitekk on January 6, 2025, adding quantum-networking technology and patents tied to linking quantum nodes. (investors.ionq.com) It followed with the acquisition of a controlling stake in ID Quantique on May 6, 2025. IonQ said that deal added quantum key distribution, quantum random number generators, single-photon detectors, and nearly 300 granted and pending patents, taking its controlled patent count to more than 900. (ionq.com) IonQ then announced on June 9, 2025 that it would acquire Oxford Ionics in a $1.075 billion transaction, combining IonQ’s systems and software with Oxford Ionics’ chip-based ion-trap technology. IonQ completed that acquisition on September 17, 2025 and said the combined company was targeting systems with 256 physical qubits at 99.99 percent accuracy by 2026. (ionq.com) (investors.ionq.com) Those deals were not drug-discovery acquisitions in the narrow sense. They were infrastructure buys: networking to connect systems, detectors to move and secure quantum signals, and chip technology to raise accuracy and scale for the chemistry workloads IonQ is trying to sell into pharma. (investors.ionq.com) (ionq.com 1) (ionq.com 2) IonQ widened the life-sciences push again on December 1, 2025, when it announced a partnership with the Centre for Commercialization of Regenerative Medicine, or CCRM. IonQ said the work would focus on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation, with initial projects in Canada and Sweden in 2026. (investors.ionq.com) The open question is whether these early chemistry demonstrations can turn into routine pharmaceutical tools. For now, IonQ has assembled a network of drug researchers, cloud providers, graphics-chip specialists, and European sites around one claim: that better molecular simulation can shave time off the longest part of drug development. (investors.ionq.com)